


a. Allyl alcohol, HCl, 60°C, 55%; b. Acetonitrile, p-toluene sulfonic acid, benzaldehyde dimethyl acetal, 55°C, 62%; c. Acetobromogalactose, Hg(CN)₂ benzene, nitromethane, 50°C, 65%; d. [Bis(methyldiphenylphosphine) (1,5-cyclo octadiene)] iridium (I) hexafluorophosphate, THF, r.t., 58%; e. CH₂Cl₂, CCl₃CN, DBU, 70%.

Scheme I

The disaccharide block is synthesized (Scheme I) by heating N-acetylgalactosamine at 60°C in dry allyl alcohol as a solvent/reactant and catalytic amount (2%) of dry HCl gas to obtain allyl glycoside in about 55% yield. 4,6-Hydroxyls are protected with benzaldehyde dimethylacetal to form 3-OH analog 4. Glycosylation with acetobromogalactose using Hg(CN)₂ as catalyst in dry benzene and nitromethane (1:1) gives the allyl disaccharide 5 in about 65% yield. Allyl group is deblocked using [Bis(methyldiphenylphosphine)(1,5-cyclo octadiene)] iridium (I) hexafluorophosphate as catalyst to obtain 1-OH of the disaccharide from which the donor 1 is formed in about 70% yield. A mixture of the donor (0.9 mmol), the acceptor (0.61 mmol) and 3Å molecular sieves (0.5 g) in 5 mL of dry THF was stirred at room temperature for 10 minutes under argon. After cooling the reaction mixture to -20 ± 5°C, 0.5 mL of 0.1 mol BF₃·Et₂O in THF was added dropwise in 10 minutes. The mixture was stirred at -20 ± 5°C for 30 minutes and warmed to room temperature. The solvent was removed in vacuo and the residue was purified by silicagel column using hexane/ethylacetate/methanol (10:10:1).

The significance of using the block donor for glycosylation, is the excellent yields of the α-glycosides 6, of serine and threonine (Scheme II). 4,6-Benzylidene may be removed using 80% aqueous acetic acid to obtain 4,6-diol 7 which may be used for the synthetic extensions, while the removal of phenacyl group gives 8 which can be used as a glycopeptide building block. C¹³ and H¹ NMR data of deblocked structures 9 are in agreement with reported data.⁹




a. N-Fmoc-L serine or threonine phenacyl ester, BF₃·OEt₂ (0.05m), -20°C, THF; b. 80% CH₃COOH in H₂O, 80°C, 73%; c. 80% CH₃COOH in EtOAc, Zinc, 90%; d. 0.1N NaOH

Scheme II

Further extension of the synthesis (Scheme III), using 4,6-diol (7) and a sialyl donor, gives sialyl-TF (10) as a building block for glycopeptide synthesis. NMR of a partially deblocked structure is in agreement with reported data.¹⁰ The reactions leading to 10 are simple and the yields are moderate to high. This disaccharide

block gives quick access to several glycopeptide building blocks including the core-2 trisaccharide (not reported here), β GlcNAc-TF, in large scale.



a. TMS-OTf, -20°C, CH₃CN, ~75% (α : β =1:1.3); b. Ac₂O, Pyridine, 80%; c. 80% CH₃COOH in EtOAc, Zinc, 82%; d. Morpholine, 81%

Scheme III

4,6-Benzylidene, in addition to being a protecting group, plays an important role in altering the overall course of the N-acetylgalactosamine reactivity exerting a significant steric control on the glycosidic bond formation. α -Glycoside is by far the dominant product while the expected side products, mainly due to the influence of 2-acetamido group, such as oxazoline and the β -glycoside are only formed in trace amounts. The table compares the yields of α - and β -glycosides from various donors and different molar ratios of serine and threonine.

Table. % Yield of serine/threonine glycosides with anomer or anomeric ratio in parentheses.

Acceptor	Donor	1	2	3
Equivalents of Serine (N-Fmoc) Phenacyl ester				
	1.5	63 (α)	45 (α)	20 (1:1)
	0.67	68 (α)	62 (α)	—
	0.33	—	72 (α)	—
Equivalents of Threonine (N-Fmoc) Phenacyl ester				
	1.5	31 (α)	20 (α)	5-10 (1:4)
	0.67	36 (α)	29 (α)	—
	0.33	—	39 (α)	—

Donors such as **1** facilitate a fast access to the related α -glycosides in large quantities, required if the industrial scale synthesis of glycopeptides is contemplated. Research into further applications of N-acetylgalactosamine based donors is on going. Block donors solve the problem of dealing with several base sensitive protecting groups on carbohydrate as well as on the serine/threonine. For example, stepwise synthesis

of a trisaccharide such as **11** becomes complicated due to the base sensitive protecting groups if monosaccharide donor **2** were to be used.

REFERENCES

- Schachter, H.; Brockhausen, I. In: *Glycoconjugates: Composition, Structure and Function*; Allen, H. J.; Kisailus, E. C. Eds.; Marcel Dekker, Inc.: New York. **1992**, 263-332.
- Yamashita, Y.; Chung, Y. S.; Horie, R.; Kannagi, R.; Sowa, M. *J. Natl. Can. Inst.* **1995**, *87*, 441-446.
- Kurosaka, A.; Nakajima, H.; Funakoshi, J.; Matsuyama, M.; Nagayo, T.; Yamashina, I. *J. Biol. Chem.* **1983**, *258*, 11594-11598.
- Fukuda, M.; Carlsson, S. R.; Klock, J. C.; Dell, A. *J. Biol. Chem.* **1986**, *261*, 12796-12806.
- Hull, S. R.; Bright, A.; Carraway, K. L.; Abe, M.; Hayes, D. F.; Kufe, D.W. *Cancer Commun.* **1989**, *1*, 261-267.
- (a) Fung, P. Y. S.; Madej, M.; Koganty, R. and Longenecker, B. M. *Cancer Res.* **1990**, *50*, 4308-4314.
(b) MacLean, G. D.; Bowen-Yacashin, M. B.; Samuel, J.; Meikle, A.; Stuart, G.; Nation, J.; Poppema, S.; Jerry, M.; Koganty, R.; Wong, T. and Longenecker, B. M. *J. Immunother.* **1992**, *11*, 292-305.
(c) MacLean, G. D.; et al. *Cancer Immunol. Immunother.* **1993**, *36*, 215-222.
(d) Longenecker, B. M.; MacLean, G. D. *The Immunologist.* **1993**, *1*, 89-93.
- (a) Kunz, H. *Angew. Chem. Int. Ed. Engl.* **1987**, *26*, 294-308.
(b) Kunz, H. *Adv. Carbohydr. Chem. Biochem.* **1994**, *50*, 277-310.
- Yule, J. E.; Wong, T. C.; Gandhi, S. S.; Qiu, D.; Riopel, M. A.; Koganty, R. R. *Tetrahedron Lett.* **1995**, *38*, 6839-6842.
- NMR data for the deblocked TF-ser/thr. (Lit. ref. Paulson, H.; Holck, J. *Carbohydr. Res.* **1982**, *109*, 89-107.)
9a, $[\alpha]_{\text{D}}^{20} + 90.0$ (c0.5, H₂O); ¹H-NMR (300 MHz, D₂O), δ =4.82 (d, 1H, J=3.5 Hz, H-1), 4.35 (d, 1H, J=8.0 Hz, H-1'), 4.24 (2d, 1H, J=3.5 and 11.5 Hz, Ser β -H), 3.39 (2d, 1H, J=8.0 and 10.5 Hz, H-2'), 1.90 (s, 3H, NAc); ¹³C-NMR (300 MHz, D₂O), δ =104.7 (C-1'), 98.3 (C-1).
9b, $[\alpha]_{\text{D}}^{20} + 92.0$ (c0.5, H₂O); ¹H-NMR (300 MHz, D₂O), δ =4.85 (d, 1H, J=3.5 Hz, H-1), 4.34 (d, 1H, J=8.0 Hz, H-1'), 4.18 (2d, 1H, J=3.5 and 11.5 Hz, Thr β -H), 3.37 (2d, 1H, J=8.0 and 10.5 Hz, H-2'), 1.92 (s, 3H, NAc), 1.29 (d, 3H, J=6.5 Hz, ThrCH₃); ¹³C-NMR (300 MHz, D₂O), δ =105.5 (C-1'), 100.1 (C-1).
- NMR data for the sialyl TF-ser. (Lit. ref. Iijima, H.; Ogawa, T. *Carbohydr. Res.* **1989**, *186*, 95-106.)
11, $[\alpha]_{\text{D}}^{20} + 40.0$ (c0.5, MeOH); ¹H-NMR (500 MHz, CD₃OD) δ =5.34-5.40 (m, 4H, H-4a, H-4c, H-8b), 5.32 (2d, 1H, J=2.2 and 8.5Hz, H-7b), 5.05 (2d, 1H, J=3.5 and 10.5Hz, H-3c), 4.94 (2d, 1H, J=7.5 and 10.5Hz, H-2c), 4.82 (d, 1H, J=3.5 Hz, H-1a), 4.72 (d, 1H, J=7.5 Hz, H-1c), 4.42 (2d, 1H, J=3.5 and 11.0Hz, H-2a), 3.82 (s, 3H, COOCH₃), 2.64 (2d, 1H, J=4.0 and 12.5Hz, H-3beq), 2.14, 2.13, 2.11, 2.10, 2.03 (6H), 2.02, 2.00 1.97, 1.93, 1.82 (10s, 33H, 9 OCOCH₃ and 2NCOCH₃).